End of September / early October 2017
Dr Vanessa Zann, Senior Research Fellow, Quotient Clinical
Dr Peter Scholes, CSO, Quotient Clinical
Nominated candidates entering clinical development often have sub-optimal physicochemical, biopharmaceutic or DMPK properties for oral delivery. Development teams are challenged with how to identify formulation strategies and design clinical programs to mitigate and overcome risks, to maximize the probability of success and avoid program delays.
Join our free seminar to hear how Quotient’s Translational Pharmaceutics platform is ideally suited to meet these needs with flexibility to adjust drug product compositions in response to emerging clinical data. Discussion topics will include:
Please click on your location preference to find out registration details.